Incorporation of 3´-Azido-3´-Deoxythymidine (AZT) Into Fetal DNA and Fetal Tissue Distribution of Drug After Infusion of Pregnant Late-Term Rhesus Macaques With a Human-Equivalent AZT Dose
- 15 December 1999
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 22 (5) , 477
- https://doi.org/10.1097/00042560-199912150-00008
Abstract
Summary: In the United States, the nucleoside analogue drug 3′-azido-3′deoxythymidine (AZT; also called zidovudine or ZDV) is given to most pregnant women who produce a positive test result for HIV-1. To investigate transplacental distribution and genotoxicity of AZT, near-term pregnant rhesus (Macacamulatta) monkeys and their fetuses were studied. Four pregnant monkeys were continuously infused with 8 mg AZT/kg body weight for the 4 hours just prior to hysterotomy at term. This short-term AZT exposure resulted in AZT incorporation into DNA of fetal liver, lung, heart, skeletal muscle, brain, testis, and placenta, which varied between 29 and 1944 molecules of AZT/106 nucleotides. In contrast, values for AZT and combined metabolites, determined by radioactivity, varied between 0.94 and 5.20 μg AZT equivalents/g tissue. A fifth animal, (H076), was infused with 17.3 mg AZT/kg body weight for ˜3 hours, followed by 1 hour without drug before hysterotomy. Similar to the 4 other monkeys, variable levels of AZT (16-147 molecules of AZT/106 nucleotides) were incorporated into organ DNA of H076, whereas organ tissues contained less-variable levels of AZT and metabolites (0.86-2.05 μg AZT equivalents/g tissue). For H076, at hysterotomy 1 hour after discontinuation of drug, values for AZT and the 3′-azido-3′-deoxythymidine-β-d-glucuronide (AZTG) in fetal blood and amniotic fluid were twofold and threefold higher than those in maternal blood. Most AZT pharmacokinetic parameters in the fifth monkey were similar to those previously reported for the first 4 monkeys and those observed in a similar study of pregnant women. These data show that a short-term AZT infusion in pregnant rhesus monkeys, which have similar AZT pharmacokinetics to those present in a pregnant human, results in incorporation of drug into the DNA of placenta and most fetal organs. Data imply that the human fetus may also be subject to incorporation of AZT into DNA even after short-term AZT infusion to the mother just before delivery.Keywords
This publication has 26 references indexed in Scilit:
- Multiorgan Transplacental and Neonatal Carcinogenicity of 3′-Azido-3′-deoxythymidine in MiceToxicology and Applied Pharmacology, 1999
- Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in EuropeBJOG: An International Journal of Obstetrics and Gynaecology, 1998
- Mechanisms and timing of mother-to-child transmission of HIV-1AIDS, 1998
- ANTIRETROVIRAL THERAPY AND INTERRUPTION OF HIV PERINATAL TRANSMISSIONImmunology and Allergy Clinics of North America, 1998
- Maternal viral load, CD4 cell count and vertical transmission of HIV-1Journal of Medical Virology, 1998
- Transplacental Effects of 3'-Azido-2',3'-Dideoxythymidine (AZT): Tumorigenicity in Mice and Genotoxicity in Mice and MonkeysJNCI Journal of the National Cancer Institute, 1997
- A Transplacental Carcinogenicity Bioassay in CD-1 Mice with ZidovudineFundamental and Applied Toxicology, 1997
- Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to InfantNew England Journal of Medicine, 1996
- Nonclinical Toxicology Studies with Zidovudine: Genetic Toxicity Tests and Carcinogenicity Bioassays in Mice and RatsFundamental and Applied Toxicology, 1996
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994